理化性质和储存条件
Molecular Weight (MW) | 613.79 |
---|
Formula | C36H47N5O4 |
---|
CAS No. | 150378-17-9 |
---|
Storage | -20℃ for 3 years in powder form |
---|
-80℃ for 2 years in solvent |
Solubility (In vitro) | DMSO: 10 mM |
---|
Water: N/A |
Ethanol: N/A |
Chemical Name | (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide |
---|
Synonyms | Indinavir, trade name: Crixivan; DRG-0233; L-735 524; DRG0233; MK-639; L 735 524; MK 639; DRG 233; L735 524; MK639; |
---|
SMILES Code | O=C([C@H]1N(C[C@@H](O)C[C@@H](CC2=CC=CC=C2)C(N[C@@H]3[C@H](O)CC4=C3C=CC=C4)=O) CCN(CC5=CC=CN=C5)C1)NC(C)(C)C |
---|
实验参考方法
Indinavir (IDV; formerly DRG-0233; MK639 and L-735524; Crixivan) is an inhibitor of HIV protease approved for use as a component of highly active antiretroviral therapy to treat HIV/AIDS. It is soluble white powder administered orally in combination with other antiviral drugs. The drug prevents protease from functioning normally. Consequently, HIV viruses cannot reproduce, causing a decrease in the viral load. Commercially sold indinavir is indinavir anhydrous, which is indinavir with an additional amine in the hydroxyethylene backbone. This enhances its solubility and oral bioavailability, making it easier for users to intake. It was synthetically produced for the purpose of inhibiting the protease in the HIV virus.
References: J Mol Biol. 2005 Dec 9;354(4):789-800; AIDS. 1996 May;10(5):485-92.
These protocols are for reference only. InvivoChem does not independently validate these methods.